Hypertension

Active Ingredient: Lisinopril

Indication for Lisinopril

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)
Therapeutic intent: Curative procedure

For this indication, competent medicine agencies globally authorize below treatments:

2.5-10 mg once daily and thereafter 20-80 mg once daily

For:

Dosage regimens

Oral, between 2.5 milligrams lisinopril and 10 milligrams lisinopril, once daily. Afterwards, oral, between 20 milligrams lisinopril and 80 milligrams lisinopril, once daily. The maximum allowed total dose is 80 milligrams lisinopril daily.

Detailed description

The dose should be individualised according to patient profile and blood pressure response.

Lisinopril may be used as monotherapy or in combination with other classes of antihypertensive therapy.

Starting dose

In patients with hypertension the usual recommended starting dose is 10 mg. Patients with a strongly activated reninangiotensin-aldosterone system (in particular, renovascular hypertension, salt and/or volume depletion, cardiac decompensation, or severe hypertension) may experience an excessive blood pressure fall following the initial dose. A starting dose of 2.5-5 mg is recommended in such patients and the initiation of treatment should take place under medical supervision. A lower starting dose is required in the presence of renal impairment.

Maintenance dose

The usual effective maintenance dosage is 20 mg administered in a single daily dose. In general, if the desired therapeutic effect cannot be achieved in a period of 2 to 4 weeks on a certain dose level, the dose can be further increased. The maximum dose used in long-term, controlled clinical trials was 80 mg/day.

Race

As with other ACE inhibitors, lisinopril may be less effective in lowering blood pressure in black patients than in non-blacks, possibly because of a higher prevalence of low-renin states in the black hypertensive population.

Dosage considerations

Lisinopril should be taken at approximately the same time each day. The absorption of lisinopril is not affected by food.

2.5-5 mg once daily and thereafter individually adjusted to a maximum dose of 20 or 40 mg once daily based on body weight

For:

Dosage regimens

Regimen A: In case that patient weight is ≥ 20 kg and patient weight is ≤ 50 kg, oral, 2.5 milligrams lisinopril, once daily. Afterwards, in case that patient weight is ≥ 20 kg and patient weight is ≤ 50 kg, oral, between 2.5 milligrams lisinopril and 20 milligrams lisinopril, once daily. The maximum allowed total dose is 20 milligrams lisinopril daily.

Regimen B: In case that patient weight is ≥ 50 kg, oral, 5 milligrams lisinopril, once daily. Afterwards, in case that patient weight is ≥ 50 kg, oral, between 5 milligrams lisinopril and 40 milligrams lisinopril, once daily. The maximum allowed total dose is 40 milligrams lisinopril daily.

Detailed description

The dose should be individualised according to patient profile and blood pressure response.

Lisinopril may be used as monotherapy or in combination with other classes of antihypertensive therapy.

Paediatric patients aged 6–16 years

The recommended initial dose is 2.5 mg once daily in patients 20 to <50 kg, and 5 mg once daily in patients ≥50 kg. The dosage should be individually adjusted to a maximum of 20 mg daily in patients weighing 20 to <50 kg, and 40 mg in patients ≥50 kg. Doses above 0.61 mg/kg (or in excess of 40 mg) have not been studied in paediatric patients.

In children with decreased renal function, a lower starting dose or increased dosing interval should be considered.

Race

As with other ACE inhibitors, lisinopril may be less effective in lowering blood pressure in black patients than in non-blacks, possibly because of a higher prevalence of low-renin states in the black hypertensive population.

Dosage considerations

Lisinopril should be taken at approximately the same time each day. The absorption of lisinopril is not affected by food.

Active ingredient

Lisinopril

Lisinopril is a peptidyl dipeptidase inhibitor. It inhibits the angiotensin-converting enzyme (ACE) that catalyses the conversion of angiotensin I to the vasoconstrictor peptide, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. Inhibition of ACE results in decreased concentrations of angiotensin II which results in decreased vasopressor activity and reduced aldosterone secretion.

Read more about Lisinopril

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.